Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition-Reference-Cited by-同舟云学术

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

Published:2017-11-20 Issue:5 Volume:110 Page:467-478
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Mitchell Rebecca¹,Hopcroft Lisa E M²,Baquero Pablo¹,Allan Elaine K³,Hewit Kay⁴,James Daniel⁴,Hamilton Graham⁵,Mukhopadhyay Arunima²,O’Prey Jim⁴,Hair Alan²,Melo Junia V⁶,Chan Edmond⁷,Ryan Kevin M⁴,Maguer-Satta Véronique⁸,Druker Brian J⁹,Clark Richard E¹⁰,Mitra Subir¹¹,Herzyk Pawel⁵¹²,Nicolini Franck E⁸,Salomoni Paolo¹³,Shanks Emma⁶,Calabretta Bruno¹⁴,Holyoake Tessa L²,Helgason G Vignir¹

Affiliation:

1. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK

2. Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK

3. Scottish National Blood Transfusion Service, Gartnavel General Hospital, Glasgow, UK

4. Cancer Research UK, Beatson Institute, Garscube Estate, Glasgow, UK

5. Glasgow Polyomics, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK

6. Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia and Imperial College, London, UK

7. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

8. Hématologie Clinique 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France

9. Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR

10. Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK

11. Department of Haematology, Milton Keynes Hospital NHS Foundation Trust, Milton Keynes, UK

12. Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK

13. Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, Paul O'Gorman Building, London, UK

14. Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/5/467/24797272/djx236.pdf

Reference47 articles.

1. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining;Rowley;Nature,1973

2. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome;Daley;Science.,1990

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med.,2006

4. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro;Graham;Blood.,2002

5. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity;Corbin;J Clin Invest.,2011

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling autophagy complexity in leukemia: The molecular landscape and possible interactions with apoptosis and ferroptosis;Cancer Letters;2024-02

2. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism;Scientific Reports;2023-08-11

3. A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch;Cell Death & Disease;2023-07-25

4. The development and benefits of metformin in various diseases;Frontiers of Medicine;2023-06

5. HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway;Human Cell;2023-05-24